- Home
- IBIO vs GOVX Comparison
IBIO vs GOVX Comparison
Compare IBIO & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- GOVX
- Stock Information
- Founded
- IBIO 2008
- GOVX 2001
- Country
- IBIO United States
- GOVX United States
- Employees
- IBIO N/A
- GOVX N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- GOVX Health Care
- Exchange
- IBIO Nasdaq
- GOVX Nasdaq
- Market Cap
- IBIO 24.3M
- GOVX 23.8M
- IPO Year
- IBIO N/A
- GOVX N/A
- Fundamental
- Price
- IBIO $2.83
- GOVX $2.22
- Analyst Decision
- IBIO Strong Buy
- GOVX Strong Buy
- Analyst Count
- IBIO 3
- GOVX 5
- Target Price
- IBIO $4.87
- GOVX $14.20
- AVG Volume (30 Days)
- IBIO 132.6K
- GOVX 759.4K
- Earning Date
- IBIO 02-07-2025
- GOVX 02-27-2025
- Dividend Yield
- IBIO N/A
- GOVX N/A
- EPS Growth
- IBIO N/A
- GOVX N/A
- EPS
- IBIO N/A
- GOVX N/A
- Revenue
- IBIO $175,000.00
- GOVX $3,090,161.00
- Revenue This Year
- IBIO N/A
- GOVX N/A
- Revenue Next Year
- IBIO N/A
- GOVX $150.51
- P/E Ratio
- IBIO N/A
- GOVX N/A
- Revenue Growth
- IBIO 250.00
- GOVX N/A
- 52 Week Low
- IBIO $1.02
- GOVX $1.09
- 52 Week High
- IBIO $4.98
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- IBIO 61.21
- GOVX 44.57
- Support Level
- IBIO $2.40
- GOVX $2.04
- Resistance Level
- IBIO $2.93
- GOVX $2.32
- Average True Range (ATR)
- IBIO 0.19
- GOVX 0.18
- MACD
- IBIO 0.04
- GOVX -0.02
- Stochastic Oscillator
- IBIO 83.87
- GOVX 25.35
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.